Hamish A Jamieson1, Prasad S Nishtala2, Richard Scrase3, Joanne M Deely4, Rebecca Abey-Nesbit5, Martin J Connolly6,7, Sarah N Hilmer8, Darrell R Abernethy9, Philip J Schluter10,11. 1. Department of Medicine, University of Otago, Christchurch: Geriatrician, Burwood Hospital, Christchurch, New Zealand. Hamish.Jamieson@otago.ac.nz. 2. School of Pharmacy, University of Otago, Dunedin, New Zealand. 3. Canterbury District Health Board, Christchurch, New Zealand. 4. Department of Medicine, University of Otago, Christchurch, New Zealand. 5. University of Otago, Christchurch, New Zealand. 6. University of Auckland, Auckland, New Zealand. 7. Waitemata District Health Board, Auckland, New Zealand. 8. The University of Sydney, Sydney, Australia. 9. Office of Clinical Pharmacology at the Food and Drug Administration, Silver Spring, MD, USA. 10. University of Canterbury-Te Whare Wānanga o Waitaha, Christchurch, New Zealand. 11. School of Nursing, Midwifery and Social Work, The University of Queensland, Brisbane, Australia.
Abstract
BACKGROUND: Adverse outcomes associated with advanced diseases are often exacerbated by polypharmacy. OBJECTIVES: The current study investigated an association between exposure to anticholinergic and sedative medicines and falls in community-dwelling older people, after controlling for potential confounders. METHODS: We conducted a retrospective cross-sectional study of a continuously recruited national cohort of community-dwelling New Zealanders aged 65 years and over. Participants had an International Resident Assessment Instrument-Home Care (interRAI-HC) assessment between 1 September 2012 and 31 January 2016. InterRAI-HC is a comprehensive, multi-domain, standardised assessment. This study captured 18 variables, including fall frequency, from the interRAI. These data were deterministically matched with the Drug Burden Index (DBI) for each participant, derived from an anonymised national dispensed pharmaceuticals database. DBI groupings were statistically ascertained, and ordinal regression models employed. RESULTS: Overall, there were 71,856 participants, with a mean age of 82.7 years (range 65-106); 43,802 (61.0%) were female, and 63,578 (88.5%) were New Zealand European. In unadjusted and adjusted analyses, DBI groupings were related to falls (p < 0.001). A DBI score > 3 was associated with a 41% increase in falls compared with a DBI score of 0 (p < 0.001). There was a 'dose-response' relationship between DBI levels and falls risk. CONCLUSIONS: DBI was found to be independently and positively associated with a greater risk of falls in this cohort after adjustment for 18 known confounders. We suggest that the DBI could be a valuable tool for clinicians to use alongside electronic prescribing to help reduce falls in older people.
BACKGROUND: Adverse outcomes associated with advanced diseases are often exacerbated by polypharmacy. OBJECTIVES: The current study investigated an association between exposure to anticholinergic and sedative medicines and falls in community-dwelling older people, after controlling for potential confounders. METHODS: We conducted a retrospective cross-sectional study of a continuously recruited national cohort of community-dwelling New Zealanders aged 65 years and over. Participants had an International Resident Assessment Instrument-Home Care (interRAI-HC) assessment between 1 September 2012 and 31 January 2016. InterRAI-HC is a comprehensive, multi-domain, standardised assessment. This study captured 18 variables, including fall frequency, from the interRAI. These data were deterministically matched with the Drug Burden Index (DBI) for each participant, derived from an anonymised national dispensed pharmaceuticals database. DBI groupings were statistically ascertained, and ordinal regression models employed. RESULTS: Overall, there were 71,856 participants, with a mean age of 82.7 years (range 65-106); 43,802 (61.0%) were female, and 63,578 (88.5%) were New Zealand European. In unadjusted and adjusted analyses, DBI groupings were related to falls (p < 0.001). A DBI score > 3 was associated with a 41% increase in falls compared with a DBI score of 0 (p < 0.001). There was a 'dose-response' relationship between DBI levels and falls risk. CONCLUSIONS:DBI was found to be independently and positively associated with a greater risk of falls in this cohort after adjustment for 18 known confounders. We suggest that the DBI could be a valuable tool for clinicians to use alongside electronic prescribing to help reduce falls in older people.
Authors: Danijela Gnjidic; Robert G Cumming; David G Le Couteur; David J Handelsman; Vasi Naganathan; Darrell R Abernethy; Sarah N Hilmer Journal: Br J Clin Pharmacol Date: 2009-07 Impact factor: 4.335
Authors: Sarah N Hilmer; Donald E Mager; Eleanor M Simonsick; Shari M Ling; B Gwen Windham; Tamara B Harris; Ronald I Shorr; Douglas C Bauer; Darrell R Abernethy Journal: Am J Med Date: 2009-12 Impact factor: 4.965
Authors: Michael B Rothberg; Shoshana J Herzig; Penelope S Pekow; Jill Avrunin; Tara Lagu; Peter K Lindenauer Journal: J Am Geriatr Soc Date: 2013-04-30 Impact factor: 7.538
Authors: Shahar Shmuel; Virginia Pate; Marc J Pepin; Janine C Bailey; Yvonne M Golightly; Laura C Hanson; Til Stürmer; Rebecca B Naumann; Danijela Gnjidic; Jennifer L Lund Journal: J Am Geriatr Soc Date: 2021-07-22 Impact factor: 5.562
Authors: Shahar Shmuel; Virginia Pate; Marc J Pepin; Janine C Bailey; Laura C Hanson; Til Stürmer; Rebecca B Naumann; Yvonne M Golightly; Danijela Gnjidic; Jennifer L Lund Journal: Pharmacoepidemiol Drug Saf Date: 2020-10-15 Impact factor: 2.890
Authors: Susan J Blalock; Chelsea P Renfro; Jessica M Robinson; Joel F Farley; Jan Busby-Whitehead; Stefanie P Ferreri Journal: BMC Geriatr Date: 2020-06-12 Impact factor: 3.921
Authors: Massirfufulay Kpehe Musa; Gizdem Akdur; Barbara Hanratty; Sarah Kelly; Adam Gordon; Guy Peryer; Karen Spilsbury; Anne Killett; Jennifer Burton; Julienne Meyer; Sue Fortescue; Ann-Marie Towers; Lisa Irvine; Claire Goodman Journal: BMJ Open Date: 2020-11-14 Impact factor: 2.692